Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases - ScienceDirect
VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease | 2 Minute Medicine
Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment of Patients with Acute Gvhd (aGVHD) - Biology of Blood and
Impact of itacitinib on xGVHD Survival (a), GVHD scoring (b) and weight... | Download Scientific Diagram
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/10-Figure1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
Itacitinib | C26H23F4N9O - PubChem
Itacitinib Clinical Trials for Chronic and Acute GVHD
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases - ScienceDirect
Cancers | Free Full-Text | Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? | HTML
Itacitinib prevents xenogeneic GVHD in humanized mice | Bone Marrow Transplantation
Incyte's Graft-Versus-Host Trial Fails to Meet Primary Endpoint | BioSpace
Itacitinib adipate | C32H33F4N9O5 - PubChem
PDF) The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
Clinical Trials of Itacitinib for Chronic and Acute GVHD
Incyte sinks as itacitinib fails pivotal test in acute GVHD | Fierce Biotech
Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease | Business Wire
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/6-Table1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/7-Table1-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
Itacitinib (INCB039110) | JAK1 Inhibitor | MedChemExpress
Ongoing clinical trials of PD-1/PD-L1 immunotherapeutics in breast cancer | Download Table
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma - ScienceDirect
Frontiers | New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions | Immunology
A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis | Clinical Research Trial Listing ( Ulcerative Colitis ) (
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease - ScienceDirect
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associa
Completed and ongoing clinical trials assessing STAT3 pathway... | Download Scientific Diagram
![PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/265b8d3517575964e518b92944c9558171cdf15d/8-Table2-1.png "PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar")
PDF] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Semantic Scholar
